Ribosomal Protein L39L Activators
Ribosomal Protein L39L activators encompass a range of chemical entities that specifically target and increase the activity or expression of Ribosomal Protein L39L (RPL39L), which is a homolog of the ribosomal protein L39. Ribosomal proteins are essential components of ribosomes, the cellular machinery responsible for synthesizing proteins by translating messenger RNA into polypeptide chains. RPL39L is part of the large ribosomal subunit and is involved in the assembly and functional dynamics of the ribosome. Activators of RPL39L may enhance its role in ribosome function, potentially affecting the rate and efficiency of protein translation. These activators could operate through various mechanisms, such as upregulating the transcription of the RPL39L gene, stabilizing RPL39L mRNA, promoting the incorporation of RPL39L into newly formed ribosomes, or by directly modulating the protein's activity within the ribosome.
The study and development of RPL39L activators require an intricate understanding of the protein's structure and its interactions within the ribosome. The chemical compounds in this class may include peptides, small molecules, or other biologically active substances that have been identified or designed to interact with RPL39L. The specificity of these activators is critical, as they must selectively engage with RPL39L without disrupting the function of other ribosomal proteins or the overall ribosome integrity. Research into RPL39L activators involves biochemical assays to measure their effects on ribosome assembly and function, as well as detailed structural analyses to determine how these compounds interact with their target.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid is a histone deacetylase inhibitor that could potentially stimulate the transcription of RPL39L by creating a more open chromatin structure conducive to gene expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine, a DNA methyltransferase inhibitor, could potentially trigger an increase in RPL39L expression by inhibiting the methylation of its promoter region, thereby permitting transcription. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $63.00 $182.00 | 8 | |
Should RPL39L have estrogen-responsive elements in its promoter region, the presence of estrogen could potentially amplify the expression of RPL39L by binding to these elements and driving transcription. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
As a potent regulator of nuclear receptor signaling, retinoic acid could potentially induce the expression of RPL39L if this gene is a target of retinoic-acid-responsive nuclear receptors. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
If RPL39L is responsive to glucocorticoids, dexamethasone, a potent glucocorticoid receptor agonist, could potentially stimulate the expression of RPL39L by activating the glucocorticoid receptor pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
By inhibiting mTOR, a central regulator of cell growth and protein synthesis, rapamycin could potentially alter the cellular landscape in a way that indirectly upregulates the expression of RPL39L. | ||||||
Hydrogen Peroxide | 7722-84-1 | sc-203336 sc-203336A sc-203336B | 100 ml 500 ml 3.8 L | $31.00 $61.00 $95.00 | 28 | |
As a potent inducer of oxidative stress responses, hydrogen peroxide might trigger a cascade of events that could lead to an increase in the expression of stress-responsive genes like RPL39L. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
As a histone deacetylase inhibitor, sodium butyrate could potentially stimulate RPL39L expression by causing a more open chromatin structure that permits transcription. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin, by intercalating into DNA and causing widespread changes in gene expression, might potentially drive an increase in RPL39L expression as part of its broad effects. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
If RPL39L has estrogen-responsive elements in its promoter region, tamoxifen, an estrogen receptor modulator, could potentially stimulate its expression depending on the cellular context. | ||||||